Pralsetinib drug interaction study for advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has come back or is not responding to standard treatments and has a RET gene change.
- You are 18 years or older.
- Your body mass index (BMI) is between 18 and 32, and you weigh at least 110 pounds (50 kg).
- You have recovered from side effects of previous treatments (except for hair loss, infertility, or mild nerve issues).
- Your kidney, liver, and blood cell counts are within acceptable ranges.
- You have not had certain heart conditions like uncontrolled heart failure, recent heart attack, or a long QT interval on EKG.
- You have not had a history of lung inflammation (pneumonitis) in the last year.
- You are not pregnant or breastfeeding, and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called pralsetinib given together with a supportive medicine (leucogen) for people whose lung cancer has a specific RET gene change. The goal is to see how well this combination works in everyday hospital care.
This study tests two drugs, pralsetinib and anlotinib, in people whose medullary thyroid cancer has spread or cannot be removed with surgery and has a specific change in the RET gene. The goal is to see how well these drugs work and how safe they are.
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.